| Exhibit 99.01 | ||
| Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com |  | |
| Press Release | ||
Results of the Annual General Meeting
Shire plc AGM – 2006Shire plc held its Annual General Meeting today. All resolutions were put to the meeting and approved on a show of hands. The proxy votes received for the meeting are set out below:
| For* | Against | Abstentions** | ||
| 1. | To receive and consider the directors’ report and accounts for the year ended 31 December 2005 | 359,071,857 (99.81%) | 675,088 (0.19%) | 1,574,434 |
| 2. | To re-elect Dr James Henry Cavanaugh as a director | 360,237,140 (99.83%) | 617,865 (0.17%) | 466,374 |
| 3. | To re-elect Mr Robin William Turnbull Buchanan as a director | 360,460,134 (99.89%) | 403,668 (0.11%) | 457,577 |
| 4. | To re-elect Mr Matthew William Emmens as a director | 358,012,655 (99.72%) | 1,004,977 (0.28%) | 2,303,747 |
| 5. | To re-elect the Honourable James Andrews Grant as a director | 357,125,147 (99.24%) | 2,752,824 (0.76%) | 1,443,408 |
| 6. | To re-elect Mr David John Kappler as a director | 358,720,911 (99.41%) | 2,140,994 (0.59%) | 459,474 |
| 7. | To elect Mr Patrick Jean Mark Langlois as a director | 360,310,235 (99.85%) | 551,670 (0.15%) | 459,474 |
| 8. | To re-elect Mr Ronald Maurice Nordmann as a director | 355,747,898 (99.84%) | 552,524 (0.16%) | 5,020,957 |
Registered in England 2883758 Registered Office as above
| 9. | To re-elect Dr Barry John Price as a director | 354,069,599 (99.37%) | 2,231,923 (0.63%) | 5,019,857 |
| 10. | To re-elect Mr Angus Charles Russell as a director | 358,109,095 (99.74%) | 916,203 (0.26%) | 2,296,081 |
| 11. | To re-appoint Deloitte & Touch LLP as Auditors | 350,604,574 (98.17%) | 6,521,791 (1.83%) | 4,195,014 |
| 12. | To authorise the Audit Committee to determine the remuneration of the Auditors | 359,770,712 (99.67%) | 1,187,866 (0.33%) | 362,801 |
| 13. | To approve the Directors’ Remuneration Report | 339,634,086 (96.79%) | 11,273,314 (3.21%) | 10,413,979 |
| 14 | To authorise the allotment of shares | 355,037,733 (98.29%) | 6,159,314 (1.71%) | 124,332 |
| 15. | To authorise the disapplication of pre-emption rights | 358,499,820 (99.26%) | 2,669,655 (0.74%) | 152,904 |
| 16. | To authorise market purchases | 361,026,133 | 238,054 | 57,192 |
| 17. | To authorise donations to EU political organisations and EU political expenditure | 354,116,165 (98.53%) | 5,286,233 (1.47%) | 1,918,981 |
| * | These figures include discretionary votes |
| ** | Abstentions are not counted in the proportion of votes “for” or “against” |
| Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
| Brian Piper (North America) | +1 484 595 8252 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system, gastrointestinal, general products and human genetic therapies. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.